Is DMAC or DNTH more undervalued in 2026?

CirclFi compares DiaMedica Therapeutics Inc. (DMAC) and Dianthus Therapeutics, Inc. (DNTH) using 13 institutional-grade valuation models. DMAC has a Quality of Company score of 4.7/10 while DNTH scores 5.5/10.

Which is a better buy — DMAC or DNTH?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DMAC and DNTH valuations compare?

DMAC at $6.16 and DNTH at $90.86 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DMAC vs DNTH Valuation Comparison 2026 — Intrinsic Value Analysis

DMAC

Biotechnology

DiaMedica Therapeutics Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$6.16

Last close

Models

7/13

Active

DNTH

Biotechnology

Dianthus Therapeutics, Inc.

Quality

5.5

out of 10

Value Trap

SAFE

Price

$90.86

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	DMAC Fair Value	DMAC Upside	DNTH Fair Value	DNTH Upside
Bayesian DCF	Intrinsic	$1.70	-72.4%	$33.65	-63.0%
Earnings Power Value	Intrinsic	—	—	$38.09	-56.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.45	-92.7%	$1.38	-98.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DMAC vs DNTH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DMAC vs DNTH — Which Stock Is More Undervalued?

DNTH scores higher with a 5.5/10 quality rating vs DMAC's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing DiaMedica Therapeutics Inc. (DMAC) and Dianthus Therapeutics, Inc. (DNTH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DMAC currently trades at $6.16 with a QOC of 4.7/10, while DNTH trades at $90.86 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).